Abdul J. Sankoh
Sage Therapeutics (United States) · 61 works · 6,060 citations · h-index 17
Top works
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- Some comments on frequently used multiple endpoint adjustment methods in clinical trials
- Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
- Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
- Effect of Zuranolone vs Placebo in Postpartum Depression
- Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues
- Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America
- An Overview of Practical Approaches for Handling Missing Data in Clinical Trials
- Trial of SAGE-217 in Patients with Major Depressive Disorder
- Use of composite endpoints in clinical trials
- A reviewer's perspective on multiple endpoint issues in clinical trials
- Zuranolone in Major Depressive Disorder
- Global Two-Group Multiple Endpoint Adjustment Methods Applied to Clinical Trials
- Interim Analyses: An Update of an FDA Reviewer’s Experience and Perspective
- Interim Analyses: An FDA Reviewer's Experience and Perspective
- SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
- The utility of mixed‐effects covariate analysis in rapid selection of doses in pediatric subjects: A case study with fexofenadine hydrochloride
- Extension of adaptive alpha allocation methods for strong control of the family‐wise error rate
- Composite and multicomponent end points in clinical trials
- SAGE-217 in Major Depressive Disorder: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial (705)